Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Presenters Stand by Posters 5:30 p.m.–7:00 p.m.<br />
P3.024 Patients Who Switched from<br />
SC IFNB-1a to Alemtuzumab in the CARE-<br />
MS II Extension Study Show Durable<br />
Improvements in Clinical Outcomes —Eva<br />
Havrdova, Douglas Arnold, Jeffrey Cohen,<br />
Alasdair Coles, Edward Fox, Hans-Peter<br />
Hartung, Krzysztof Selmaj, David Margolin,<br />
Linda Kasten, D Alastair Compston<br />
P3.025 Patients Who Discontinued SC<br />
IFNB-1a and Switched to Alemtuzumab<br />
in the CARE-MS II Extension Study<br />
Show Durable Reduction in New Lesion<br />
Activity —Daniel Pelletier, Jeffrey Cohen,<br />
Alasdair Coles, Edward Fox, Hans-Peter<br />
Hartung, Eva Havrdova, Krzysztof Selmaj,<br />
David Margolin, Karthinathan Thangavelu,<br />
Douglas Arnold<br />
P3.026 Patients Who Discontinued SC<br />
IFNB-1a and Switched to Alemtuzumab<br />
in the CARE-MS I Extension Study<br />
Show Durable Reduction in New Lesion<br />
Activity —Alex Rovira, Jeffrey Cohen,<br />
Alasdair Coles, Edward Fox, Hans-Peter<br />
Hartung, Eva Havrdova, Krzysztof Selmaj,<br />
David Margolin, Karthinathan Thangavelu,<br />
Douglas Arnold<br />
P3.027 Final Outcomes of the<br />
Teriflunomide Phase 2 Extension Study:<br />
13 Years of Efficacy and Safety Results —<br />
Marcelo Kremenchutzky, Mark Freedman,<br />
Amit Bar-Or, Annie Purvis, Myriam Benamor,<br />
Philippe Truffinet, Paul O’Connor<br />
P3.028 Clinical Efficacy of Cladribine<br />
Tablets in Patients with Relapsing-<br />
Remitting Multiple Sclerosis (RRMS): Final<br />
Results from the 120-Week Phase IIIb<br />
Extension Trial to the CLARITY Study —<br />
Gavin Giovannoni, Giancarlo Comi, Stuart<br />
Cook, Peter Rieckmann, Kottil Rammohan,<br />
Per Soelberg-Soerensenn, Patrick Vermersch,<br />
Emily Martin, Fernando Dangond<br />
P3.029 Efficacy of Cladribine Tablets<br />
As Add-On to IFN-beta Therapy in<br />
Patients with Active Relapsing MS: Final<br />
Results from the Phase II ONWARD<br />
Study —Xavier Montalban, Bruce Cohen,<br />
Thomas Leist, Harold Moses, Christine<br />
Hicking, Fernando Dangond<br />
P3.030 Baseline Characteristics of<br />
Patients in the PANGAEA Study —Tjalf<br />
Ziemssen, Christian Cornelissen, Jennie<br />
Medin<br />
P3.031 PANGAEA 2.0: State of the Art<br />
Multiple Sclerosis Patient Management<br />
in Daily Clinical Practice. A 3-Year<br />
Observational Study of Patients Receiving<br />
Fingolimod —Tjalf Ziemssen, Raimar Kern,<br />
Christian Cornelissen<br />
P3.032 Siponimod (BAF312) Safety,<br />
Tolerability and Pharmacodynamics in<br />
Healthy Subjects with Different Genetic<br />
Variants of the Cytochrome(P450)2C9<br />
Enzyme —Mike Ufer, Anne Gardin,<br />
Gianluca Rossato, Zhenzhong Su, Yi Jin, Eric<br />
Legangneux, Kasra Shakeri-Nejad<br />
P3.033 Longer-Term Follow-Up of the<br />
Efficacy of Delayed-Release Dimethyl<br />
Fumarate in Newly Diagnosed Patients<br />
with Relapsing-Remitting Multiple<br />
Sclerosis: Integrated Analysis of DEFINE,<br />
CONFIRM, and ENDORSE —Ralf Gold,<br />
Gavin Giovannoni, J. Theodore Phillips,<br />
Robert Fox, Annie Zhang, Catherine Taylor,<br />
Jing Marantz<br />
P3.034 A Randomized, Double-<br />
Blind, Parallel Group Study to Compare<br />
the Safety and Efficacy of Arbaclofen<br />
Extended Release Tablets to Placebo and<br />
Baclofen for the Treatment of Spasticity in<br />
Patients with Multiple Sclerosis —Daniel<br />
Kantor, Daniel Wynn, Angela Dentiste, Mark<br />
Aikman, Praveen Tyle, Samer Kaba<br />
P3.035 Efficacy of Cladribine<br />
Tablets in ORACLE Study Patients Who<br />
Retrospectively Met 2010 McDonald<br />
Multiple Sclerosis (MS) Criteria at<br />
Baseline —Mark Freedman, Thomas Leist,<br />
Giancarlo Comi, Bruce Cree, Patricia Coyle,<br />
Hans-Peter Hartung, Patrick Vermersch, Doris<br />
Damian, Fernando Dangond<br />
P3.036 Interferon β-1a SC Tiw<br />
Reduces Mild to Moderate and Moderate<br />
to Severe Relapses and Disease Activity<br />
over 1 Year in Patients with Relapsing MS:<br />
Post Hoc Analyses of PRISMS Data —<br />
Aaron Boster, David Li, Eric Williamson,<br />
Juanzhi Fang, Fernando Dangond, Anthony<br />
Traboulsee<br />
P3.037 Treatment Adherence,<br />
Persistence, and Compliance at 96 Weeks<br />
in MS Patients Using RebiSmart ® for<br />
Injection of Interferon β-1a —Virginia<br />
Devonshire, Anthony Feinstein, Alan Gillett<br />
P3.038 Outcomes in Patients with<br />
Progressive MS: Analysis of Teriflunomide<br />
Long-Term Extension Data —Flavia Nelson,<br />
Christine Lebrun-Frenay, William Camu,<br />
Alexey Boyko, Karthinathan Thangavelu,<br />
Pascal Rufi, Steve Cavalier, Philippe Truffinet,<br />
Jinjun Liang, Fred Lublin<br />
P3.039 High Dose Biotin As Treatment<br />
for Progressive Multiple Sclerosis —Gary<br />
Birnbaum, Jessica Stulc, Tori Snyder<br />
P3.040 Hormone Therapy Use and<br />
Physical Quality of Life in Postmenopausal<br />
Women with Multiple Sclerosis —Riley<br />
Bove, Charles White, Kathryn Fitzgerald,<br />
Tanuja Chitnis, Lori Chibnik, Alberto Ascherio,<br />
Kassandra Munger<br />
P3.041 Correlation of Physical,<br />
Cognitive and MRI Measures with<br />
Multifocal Visual Evoked Potential Using<br />
Baseline Data from the Anti-LINGO-1<br />
SYNERGY Trial in Multiple Sclerosis —<br />
Diego Cadavid, Alexander Klistorner, Radek<br />
Ampapa, Robert Bonek, Jelena Drulovic,<br />
Smiljana Kostić, Maciej Maciejowski,<br />
Krzysztof Selmaj, Martin Vališ, Tomasz<br />
Zielinski, Adama Ibrahim, Yiwei Zhang, Lei Xu<br />
P3.042 Multiple Intrathecal Dosing<br />
of Neural Progenitors Administered to<br />
Progressive MS Patients with Disability<br />
Is Safe and Improves Disability Scores —<br />
Saud Sadiq, Leslie Blackshear, Gloria Joo,<br />
Tamara Vyshkina, Violaine Harris<br />
P3.043 NDC-1308, a Small Molecule<br />
with Remyelinating Activity for Treatment<br />
of Secondary Progressive Multiple<br />
Sclerosis Patients —Steven Nye, James<br />
Yarger<br />
P3.044 Who Participates in<br />
MS Clinical Trials? The NARCOMS<br />
Experience —Stacey Cofield, Tuula Tyry,<br />
Amber Salter, Sandre McNeal, Robert Fox,<br />
Ruth-Ann Marrie, Gary Cutter<br />
P3.045 A Multicenter Randomized<br />
Controlled Trial in People with Multiple<br />
Sclerosis Comparing the Immediate and<br />
6-Month Follow-Up Effects of Two Group<br />
Programs on Fatigue and Self-Efficacy —<br />
Cinda Hugos, Yiyi Chen, Zunqiu Chen, Aaron<br />
Turner, Jodie Haselkorn, Toni Chiara, Sean<br />
McCoy, Christopher Bever, Dennis Bourdette<br />
P3.046 Baseline Immunological<br />
Profile in Secondary Progressive Multiple<br />
Sclerosis Patients of Phase III EXPAND<br />
Trial —Yang Mao-Draayer, Qi Wu, Qin Wang,<br />
Catherine Dowling, Steven Lundy, Benjamin<br />
Segal, Wallström Wallström<br />
P3.047 Teriflunomide Significantly<br />
Slows Brain Volume Loss in MS Patients<br />
Irrespective of Disability Progression —Till<br />
Sprenger, Luwig Kappos, Ernst-Wilhelm<br />
Radue, Laura Gaetano, Nicole Mueller-Lenke,<br />
Jens Wuerfel, Karthinathan Thangavelu,<br />
Michael Panzara, Steve Cavalier, Jerry<br />
Wolinsky<br />
P3.048 High Dose Clinical<br />
Pharmacology Study of GNBAC1, a<br />
Humanized Monoclonal Antibody for<br />
Multiple Sclerosis —Francois Curtin, Herve<br />
Porchet, Alois Lang<br />
P3.049 Disease-Modifying Treatment<br />
Has a Similar Effect in Pediatric Onset<br />
and Adult Onset RRMS Patients: Findings<br />
from an Integrated RRMS Adult Clinical<br />
Trial Database —Teesta Soman, Carmen<br />
Castrillo, Kartik Raghupathi<br />
P3.050 The Use of Natalizumab in<br />
Pediatric-Onset Multiple Sclerosis —<br />
Samar Ahmed, Jasem Al-Hashel, Raed<br />
Behbehani, Raed Alroughani<br />
P3.051 Clinical Efficacy of Laquinimod<br />
0.6 Mg Once Daily in the Treatment of<br />
Worsening Relapsing-Remitting Multiple<br />
Sclerosis (Baseline EDSS >3) —Timothy<br />
Vollmer, Giancarlo Comi, Ludwig Kappos,<br />
Xavier Montalban, Gary Cutter, Joshua<br />
Steinerman, Nissim Sasson, Tali Gorfine,<br />
Volker Knappertz<br />
P3.052 Teriflunomide Slows Brain<br />
Volume Loss: Subgroup Analysis of the<br />
SIENA TEMSO MRI Dataset —Jens<br />
Wuerfel, Ludwig Kappos, Ernst-Wilhelm<br />
Radue, Laura Gaetano, Nicole Mueller-Lenke,<br />
Karthinathan Thangavelu, Michael Panzara,<br />
Steven Cavalier, Jerry Wolinsky, Till Sprenger<br />
P3.053 Durable Efficacy of<br />
Alemtuzumab Over 10 Years: Long-Term<br />
Follow-Up of Patients with RRMS from<br />
the CAMMS223 Study —Alasdair Coles,<br />
Mario Habek, Ann Bass, Vesna Brinar, Anton<br />
Vladic, David Margolin, Minmin Lu, Edward<br />
Fox<br />
P3.054 Long-Term Responders from<br />
the CARE-MS I Study: No Evidence of<br />
Disease Activity for 4 Years Following<br />
2 Courses of Alemtuzumab and No<br />
Further Treatment —Gavin Giovannoni,<br />
Douglas Arnold, Jeffrey Cohen, Alasdair<br />
Coles, Edward Fox, Hans-Peter Hartung, Eva<br />
Havrdova, Krzysztof Selmaj, David Margolin,<br />
Karthinathan Thangavelu, Michael Panzara,<br />
Heinz Wiendl<br />
P3.055 Long-Term Clinical Stability<br />
in a Subset of MS Patients with Minimal<br />
Therapeutic Intervention —Leslie<br />
Blackshear, Lena Josephs, Saud Sadiq<br />
P3.056 Estimation of Brain Volume<br />
Loss with Multiple Imputation of Missing<br />
Values in the Placebo-Controlled<br />
FREEDOMS Trials of Fingolimod —Gary<br />
Cutter, Xiangyi Meng, Brandon Brown<br />
P3.057 Ongoing Safety and<br />
Effectiveness: An Interim Analysis of<br />
Long-Term Fingolimod Treatment —Jeffrey<br />
Cohen, Ashish Pradhan, Rebecca Gottschalk,<br />
Yu Chen, Ludwig Kappos<br />
P3.058 Slowing of Disability<br />
Progression Based on 6-Month Confirmed<br />
EDSS in Patients with Relapsing-<br />
Remitting Multiple Sclerosis (RRMS)<br />
Treated with Cladribine Tablets in the<br />
CLARITY Study: A Post-Hoc Subgroup<br />
Analysis —Stuart Cook, Kottil Rammohan,<br />
Peter Rieckmann, Per Soelberg-Sørensenn,<br />
Patrick Vermersch, Christine Hicking,<br />
Fernando Dangond, Gavin Giovannoni<br />
P3.059 No Evidence of Disease<br />
Activity for 4 Years Following 2 Courses<br />
of Alemtuzumab and No Further<br />
Treatment: Long-Term Responders from<br />
the CARE-MS II Study —Heinz Wiendl,<br />
Douglas Arnold, Jeffrey Cohen, Alasdair<br />
Coles, Edward Fox, Hans-Peter Hartung, Eva<br />
Havrdova, Krzysztof Selmaj, David Margolin,<br />
Karthinathan Thangavelu, Michael Panzara,<br />
Gavin Giovannoni<br />
P3.060 Dimethylfumarate in Real-Life:<br />
Efficacy and Safety in a Monocentric<br />
Prospective Cohort of 156 Patients with<br />
MS —Jennifer Aboab, Antoine Gueguen,<br />
Romain Deschamps, Caroline Bensa, Antoine<br />
Moulignier, Olivier Gout<br />
P3.061 Rate of Brain Volume Loss with<br />
Long-Term Delayed-Release Dimethyl<br />
Fumarate Treatment in Patients with<br />
Relapsing-Remitting Multiple Sclerosis:<br />
6-Year Results from ENDORSE —Ludwig<br />
Kappos, Tarek Yousry, Robert Fox, Ralf Gold,<br />
Douglas Arnold, James Potts, Jing Marantz<br />
P3.062 Effect of Teriflunomide<br />
(Aubagio ® ) on Gray Matter Pathology<br />
in Multiple Sclerosis —Robert Zivadinov,<br />
Channa Kolb, Noopur Modi, Jillian Carl,<br />
Jesper Hagemeier, Niels Bergsland, Deepa<br />
Ramasamy, Jackie Durfee, Bianca Weinstock-<br />
Guttman<br />
P3.063 Lymphocyte Subtypes<br />
in Relapsing Remitting Multiple<br />
Sclerosis (RRMS) Patients Treated with<br />
Dimethylfumarate (DMF)—Rik Ganguly,<br />
Ann Camac, Caitlin Dionne, Claudia Chaves<br />
P3.064 Regulatory B Cells Increased<br />
Following Treatment of Relapsing<br />
Remitting Multiple Sclerosis Patients with<br />
BG-12 —Yang Mao-Draayer, Steven Lundy, Qi<br />
Wu, Qin Wang, Catherine Dowling, Sophina<br />
Taitano, Guangmei Mao<br />
P3.065 JC Virus Antibody Testing<br />
in the Penn MS Clinic - Examining the<br />
Utility and Stability of the Test —Christine<br />
Bierema, Eric Williamson<br />
Mon · April 18<br />
Fast and easy registration · AAN.com/view/AM16 69
Change language